Ind-Swift Laboratories Analysis

dividend

Pros

Cons

• Unable to calculate sustainability of dividends as Ind-Swift Laboratories has not reported any payouts.
• Unable to evaluate Ind-Swift Laboratories's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
• Unable to evaluate Ind-Swift Laboratories's dividend against the top 25% market benchmark as the company has not reported any payouts.

health

Pros

• Ind-Swift Laboratories is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
• Whilst loss making Ind-Swift Laboratories has sufficient cash runway for more than 3 years, due to free cash flow being positive and growing by 1.4% per year.
• Whilst loss making Ind-Swift Laboratories has sufficient cash runway for more than 3 years if it maintains the current positive free cash flow level.
• The level of debt compared to net worth has been reduced over the past 5 years (223.2% vs 188.2% today).

Cons

• Debt is not well covered by operating cash flow (13.1%, less than 20% of total debt).
• Debt is not covered by short term assets, assets are 0.8x debt.
• Ind-Swift Laboratories's long term commitments exceed its cash and other short term assets.
• Ind-Swift Laboratories is making a loss, therefore interest payments are not well covered by earnings.
• Ind-Swift Laboratories's level of debt (188.2%) compared to net worth is high (greater than 40%).
• High level of physical assets or inventory.

management

Pros

• The tenure for the Ind-Swift Laboratories board of directors is about average.
• Nav's compensation has been consistent with company performance over the past year, both up more than 20%.
• The average tenure for the Ind-Swift Laboratories management team is over 5 years, this suggests they are a seasoned and experienced team.

Cons

• Nav's remuneration is higher than average for companies of similar size in India.

misc

Pros

Cons

• Ind-Swift Laboratories is not covered by any analysts.
• Ind-Swift Laboratories has significant price volatility in the past 3 months.

past

Pros

Cons

• Unable to compare Ind-Swift Laboratories's 1-year earnings growth to the 5-year average as it is not currently profitable.
• Ind-Swift Laboratories does not make a profit even though their year on year earnings growth rate was positive over the past 5 years.
• Ind-Swift Laboratories used its assets less efficiently than the IN Pharmaceuticals industry average last year based on Return on Assets.
• It is difficult to establish if Ind-Swift Laboratories improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
• It is difficult to establish if Ind-Swift Laboratories has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
• Unable to compare Ind-Swift Laboratories's 1-year growth to the IN Pharmaceuticals industry average as it is not currently profitable.

value

Pros

• Ind-Swift Laboratories's share price is below the future cash flow value, and at a moderate discount (> 20%).
• Ind-Swift Laboratories's share price is below the future cash flow value, and at a substantial discount (> 40%).
• Ind-Swift Laboratories is good value based on assets compared to the IN Pharmaceuticals industry average.
• INDSWFTLAB outperformed the Market in India which returned -14.5% over the past year.
• NSEI:INDSWFTLAB is up 32.5% outperforming the Pharmaceuticals industry which returned 6.8% over the past month.
• NSEI:INDSWFTLAB is up 32.5% outperforming the market in India which returned 8% over the past month.

Cons

• Ind-Swift Laboratories is loss making, we can't compare its value to the IN Pharmaceuticals industry average.
• Ind-Swift Laboratories is loss making, we can't compare the value of its earnings to the India market.
• INDSWFTLAB underperformed the Pharmaceuticals industry which returned 26.7% over the past year.